Press Release

Cognition Therapeutics Receives $7.3 Million Through two NIA Grant to Further Development of CT1812

PITTSBURGH, July 5, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced the receipt of two grants expected to total $7.3 million from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). Grant RF1AG057553 provides $4.8 million to conduct the SPARC (Synaptic Protection for Alzheimer’s Restoration of Cognition) Study; and grant 1RF1AG057780 provides $2.5 million to conduct SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients). Applications for both grants were submitted in the first quarter of 2017.

SPARC will be designed to compare changes in synaptic density in 21  individuals with mild-to-moderate Alzheimer’s diseases while SNAP will measure the concentration of Aβ oligomers in the CSF of 18 mild-to-moderate Alzheimer’s patients following a single dose of Elayta or placebo. More details on these studies will be provided upon their initiation, which we expect to occur in the first half of 2018. 

About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule. This highly brain penetrant compound targets the sigma-2 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. In Cognition’s recently completed Study COG0102, patients with mild-to-moderate Alzheimer’s disease were randomized to one of three doses of CT1812 or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Detailed results of this Phase 1b/2 study are anticipated to be announced at the CTAD (Clinical Trials on Alzheimer’s disease) meeting in Boston in November 2017. Additional information about Cognition may be found online at https://cogrx.com.

Scroll to Top